On-cycle HCG blast + Nolva taper
HCG the final weeks of a cycle followed by Nolvadex taper.
Concentration over time
| Date | HCG | Nolvadex (Tamoxifen) |
|---|---|---|
| W1 | 0.00 | 0.00 |
| W2 | 2994.07 | 0.00 |
| W3 | 2308.07 | 0.00 |
| W5 | 170.60 | 0.00 |
| W6 | 4.83 | 0.00 |
| W8 | 0.00 | 0.00 |
| W4 | 0.00 | |
| W5 | 557.94 | |
| W6 | 589.08 | |
| W6 | 694.46 | |
| W7 | 577.10 | |
| W8 | 665.85 | |
| W8 | 652.45 |
Protocol summary
On-cycle HCG blast + Nolva taper · 8 weeks starting Jul 20, 26
- HCG — 500 mcg 3×/week (Mon/Wed/Fri), weeks 0–3
- Nolvadex (Tamoxifen) — 20.0 mg Every day, weeks 4–8
Protocol overview
- Category
- pct
- Duration
- 8 weeks
- Compounds
- 2
- Tags
- pct, hcg, nolva
Compounds in this protocol
How to read this protocol
The chart above shows the modeled blood concentration of each compound over the 8-week duration. Each compound accumulates toward steady state (roughly 5 half-lives). The peak-to-trough ratio within each dose interval depends on the injection frequency relative to the half-life.
Use the [peak-trough estimator](/tools/peak-trough) to see predicted levels at any point, or the [clearance calculator](/tools/clearance) to estimate washout after the protocol ends. The [PCT planner](/pct-planner) estimates when to start post-cycle therapy.
Educational only. Not medical advice. Concentration values are modeled estimates based on population pharmacokinetics, not predictions of individual blood levels.